These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 247480)

  • 21. Adriamycin-cyclophosphamide and adriamycin-cis-dichloro-diammineplatinum(II) combination chemotherapy in patients with advanced cancer.
    Higby DJ; Wilbur D; Wallace HJ; Henderson ES; Weiss R
    Cancer Treat Rep; 1977 Aug; 61(5):869-73. PubMed ID: 329980
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Determination of leucine arylamidase (LAS) activity in the urine during the monitoring of cisplatin nephrotoxicity in oncologic diseases].
    Vorlícek J; Nekulová M; Mechl Z; Skalková D
    Vnitr Lek; 1985 Sep; 31(9):887-93. PubMed ID: 4049766
    [No Abstract]   [Full Text] [Related]  

  • 23. Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity.
    Campbell AB; Kalman SM; Jacobs C
    Cancer Treat Rep; 1983 Feb; 67(2):169-72. PubMed ID: 6681731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tetany: a complication of cis-dichlorodiammineplatinum(II) therapy.
    Hayes FA; Green AA; Senzer N; Pratt CB
    Cancer Treat Rep; 1979 Apr; 63(4):547-8. PubMed ID: 445508
    [No Abstract]   [Full Text] [Related]  

  • 25. cis-Dichlorodiammineplatinum(II) in the treatment of esophageal carcinoma.
    Davis S; Shanmugathasa M; Kessler W
    Cancer Treat Rep; 1980; 64(4-5):709-11. PubMed ID: 7191780
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Model independent pharmacokinetic study of cis-dichlorodiammineplatinum (II).
    Dumas M; d'Athis P; de Gislain C; Escousse A; Guerrin J; Autissier N
    Int J Clin Pharmacol Ther Toxicol; 1985 Aug; 23(8):430-3. PubMed ID: 4044076
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single-agent cis-platinum therapy for advanced ovarian cancer.
    Gershenson DM; Wharton JT; Herson J; Edwards CL; Rutledge FN
    Obstet Gynecol; 1981 Oct; 58(4):487-96. PubMed ID: 7024883
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Weekly administration of cis-diamminedichloroplatinum (II) without hydration or osmotic diuresis.
    Randolph VL; Wittes RE
    Eur J Cancer (1965); 1978 Jul; 14(7):753-6. PubMed ID: 658099
    [No Abstract]   [Full Text] [Related]  

  • 29. [Prospects for using platinum coordination compounds possessing antitumor activity].
    Sidorik EP; Burlaka AP; Sirdorik OA; Korchevaia LM
    Eksp Onkol; 1984; 6(6):6-12. PubMed ID: 6396067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nursing care of patients experiencing cisplatin-related peripheral neuropathy.
    Holden S; Felde G
    Oncol Nurs Forum; 1987; 14(1):13-7. PubMed ID: 3027676
    [No Abstract]   [Full Text] [Related]  

  • 31. Prevalence of nephrotoxicosis associated with a short-term saline solution diuresis protocol for the administration of cisplatin to dogs with malignant tumors: 61 cases (1987-1989).
    Ogilvie GK; Straw RC; Powers BE; Cooper MF; Withrow SJ
    J Am Vet Med Assoc; 1991 Sep; 199(5):613-6. PubMed ID: 1787122
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cis-platinum in cancer chemotherapy: a significant advance.
    Helmers R; Clamon G
    J Iowa Med Soc; 1982 Nov; 72(11):464-5, 468. PubMed ID: 6890970
    [No Abstract]   [Full Text] [Related]  

  • 33. High-dose cis-diamminedichloro-platinum therapy in patients with advanced breast cancer: pharmacokinetics, toxicity, and therapeutic efficacy.
    Ostrow S; Egorin M; Aisner J; Bachur N; Wiernik PH
    Cancer Clin Trials; 1980; 3(1):23-7. PubMed ID: 7190082
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cisplatin (platidiam) and the prospects for using complex platinum compounds in the clinical chemotherapy of malignant tumors].
    Gorbunova VA
    Vopr Onkol; 1989; 35(3):325-30. PubMed ID: 2705315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical trial of combined therapy with adriamycin and cis-dichlorodiammineplatinum(II).
    Mills RC; Maurer LH; Forcier RJ; Grace WR; Burke GP; Karp DD; Smith RC; Mcintyre OR; Bean C
    Cancer Treat Rep; 1977; 61(3):477-9. PubMed ID: 872146
    [No Abstract]   [Full Text] [Related]  

  • 36. Antitumor activity, induction of cross-resistance, and nephrotoxicity of a new platinum analogue, cis-1,1-diaminomethylcyclohexaneplatinum(II) sulfate, and of cis-diamminedichloroplatinum(II) in an immunocytoma model in the LOU/M rat.
    de Jong WH; Steerenberg PA; Vos JG; Bulten EJ; Verbeek F; Kruizinga W; Ruitenberg EJ
    Cancer Res; 1983 Oct; 43(10):4927-34. PubMed ID: 6683993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical pharmacology and pharmacokinetics of cis-platinum and analogs.
    Ribaud P; Gouveia J; Bonnay M; Mathe G
    Cancer Treat Rep; 1981; 65 Suppl 3():97-105. PubMed ID: 7049371
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diamminodichloride platinum (cis-platinum) in the treatment of hepatocellular carcinoma.
    Melia WM; Westaby D; Williams R
    Clin Oncol; 1981 Dec; 7(4):275-80. PubMed ID: 6172230
    [No Abstract]   [Full Text] [Related]  

  • 39. [Platinum derivatives in pediatric oncology].
    Doz F; Pinkerton R; Pacquement H; Michon J; Quintana E; Bastian G; Chazard M; Pellae-Cosset B; Zucker JM
    Arch Fr Pediatr; 1993 Apr; 50(4):353-9. PubMed ID: 8379826
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacokinetics of non-protein-bound platinum species following administration of cis-dichlorodiammineplatinum(II).
    Belt RJ; Himmelstein KJ; Patton TF; Bannister SJ; Sternson LA; Repta AJ
    Cancer Treat Rep; 1979; 63(9-10):1515-21. PubMed ID: 498151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.